In an otherwise healthy adult with uncomplicated primary hypertension and no contraindications, which antihypertensive agents (including losartan and amlodipine) are preferred and how do they rank by overall tolerability, side‑effect profile, and discontinuation rates?

Preferred Antihypertensive Agents: Ranking by Tolerability, Side Effects, and Discontinuation Rates

Primary Recommendation

For uncomplicated primary hypertension, thiazide diuretics, ACE inhibitors, ARBs (including losartan), and calcium channel blockers (including amlodipine) are all first-line agents with comparable efficacy, but they differ significantly in tolerability—with losartan demonstrating superior tolerability over amlodipine, particularly regarding discontinuation rates and drug-related adverse events. 1, 2

---

Ranking by Overall Tolerability and Discontinuation Rates

1. ARBs (Losartan) - Best Tolerability Profile

• Discontinuation rates: 4.4% due to drug-related adverse events 1
• Total adverse event incidence: 67.8% (any adverse event), 25.5% (drug-related) 1
• Most common side effects: Dizziness (6.0%), upper respiratory infection (8%), back pain (2%), nasal congestion (2%) 3, 1
• Cough incidence: 17-29% in patients previously experiencing ACE inhibitor cough—similar to placebo/hydrochlorothiazide 3
• Key advantage: Minimal peripheral edema (2.5%) compared to calcium channel blockers 1

2. Thiazide Diuretics - Cost-Effective with Moderate Tolerability

• Recommended as first-line when no compelling indications exist 4
• Chlorthalidone and indapamide preferred over hydrochlorothiazide for cardiovascular outcomes, providing 7-8 mmHg additional SBP reduction 4
• Common side effects: Metabolic disturbances (glucose intolerance, dyslipidemia), hypokalemia, hyperuricemia 4
• Contraindications: Gout (compelling), metabolic syndrome (possible) 4

3. Calcium Channel Blockers (Amlodipine) - Effective but Less Well-Tolerated

• Discontinuation rates: 12.9% due to drug-related adverse events 1
• Total adverse event incidence: 79.8% (any adverse event), 43.8% (drug-related) 1
• Most common side effect: Lower-extremity edema (24.0%)—significantly higher than losartan 1
• Other side effects: Headache, flushing, dizziness (4.0%) 5, 1
• Blood pressure efficacy: Slightly greater absolute BP reduction than losartan in some studies (12.6 vs 10.3 mmHg diastolic) 6, but comparable in others 1

4. ACE Inhibitors - Effective but Limited by Cough

• Discontinuation: Persistent dry cough occurs in "a few percent" and is a leading cause of therapy discontinuation 3
• Cough incidence: 62-69% in rechallenge studies 3
• Other side effects: Angioedema (rare but serious), hyperkalemia, acute renal failure in bilateral renal artery stenosis 4
• Compelling contraindications: Pregnancy, angioedema history, bilateral renal artery stenosis 4

---

Direct Comparison: Losartan vs. Amlodipine

Efficacy

• Blood pressure reduction: Comparable overall, with losartan showing non-inferiority in isolated systolic hypertension (27.4 vs 28.1 mmHg SBP reduction) 1
• Response rates: Similar (73.9% losartan vs 75.4% amlodipine achieving target <140 mmHg or ≥20 mmHg reduction) 1
• Blood pressure variability: Amlodipine may provide better control of visit-to-visit and day-to-day BP variability 7

Tolerability Advantage: Losartan

• Drug-related adverse events: 25.5% (losartan) vs 43.8% (amlodipine)—nearly half the rate 1
• Discontinuation due to adverse events: 4.4% (losartan) vs 12.9% (amlodipine)—three times lower 1
• Peripheral edema: 2.5% (losartan) vs 24.0% (amlodipine)—ten-fold difference 1
• Quality of life: Losartan improved Psychological General Well-Being index scores in some domains, while amlodipine showed no change 2

Special Population Considerations

• African American patients: Amlodipine showed higher response rates (62.5% vs 41.4%) 6, consistent with guideline recommendations for calcium channel blockers or thiazides as first-line in Black adults 4, 8
• Elderly with isolated systolic hypertension: Both equally effective 1
• Patients with gout: Losartan preferred due to modest urate-lowering effects 9

---

Ability to Withdraw/Discontinue Therapy

Low Withdrawal Risk

• Losartan and other ARBs: No rebound hypertension or withdrawal syndrome reported 10
• Amlodipine: Long half-life allows gradual washout; no significant withdrawal syndrome 5
• Thiazide diuretics: Can be discontinued without rebound 4

High Withdrawal Risk

• Clonidine (centrally acting agent): Severe withdrawal syndrome with restlessness, sweating, anxiety, rebound hypertension, elevated catecholamines, and rare fatalities 10
• Beta-blockers: Potential for rebound tachycardia and hypertension, particularly with short-acting agents 4
• Methyldopa: Withdrawal syndrome possible but less severe than clonidine 10

---

Practical Treatment Algorithm

Step 1: Initial Monotherapy Selection

• No compelling indications: Start with thiazide diuretic (lowest cost) or losartan (best tolerability) 4
• Black patients without CKD/HF: Prefer amlodipine or thiazide 4, 8
• Diabetes, CKD, or proteinuria: Prefer losartan or ACE inhibitor 4
• Left ventricular hypertrophy: Prefer losartan (proven superiority over beta-blockers in LIFE trial) 4, 11

Step 2: Combination Therapy (Most Patients Require ≥2 Drugs)

• Logical combinations: (ACE inhibitor or ARB) + (calcium channel blocker or thiazide) 4
• Avoid: ACE inhibitor + ARB + renin inhibitor (potentially harmful) 4
• Stage 2 hypertension (≥140/90 mmHg): Consider starting with 2-drug combination 4

Step 3: Resistant Hypertension

• Third agent: Add spironolactone 12.5-25 mg daily (if eGFR >45 mL/min and K+ <4.5 mEq/L) 4
• Fourth agent: Beta-blocker if heart rate >80 bpm, or central alpha-2 agonist 4
• Fifth agent: Hydralazine (<150 mg/day to avoid drug-induced lupus) 4

---

Critical Monitoring and Safety

Losartan-Specific Monitoring

• Check serum potassium and creatinine within 2-4 weeks of initiation, especially with CKD 9
• Contraindications: Pregnancy (fetal harm), bilateral renal artery stenosis, hyperkalemia 4, 9, 3
• Avoid combination with ACE inhibitors or aliskiren (increased hypotension, hyperkalemia, AKI without benefit) 4, 9

Amlodipine-Specific Monitoring

• Watch for peripheral edema (most common reason for discontinuation) 1
• Can be dosed at any time of day for adherence 8
• No specific laboratory monitoring required 5

---

Common Pitfalls to Avoid

1. Underdosing losartan: The European Journal of Heart Failure suggests 50 mg daily may be suboptimal; consider titrating to 100 mg daily for maximal benefit, particularly in heart failure 11

2. Using hydrochlorothiazide instead of chlorthalidone/indapamide: Thiazide-like diuretics provide superior cardiovascular outcomes 4

3. Combining beta-blockers with thiazides in diabetes-prone patients: Increased risk of new-onset diabetes, especially in obese patients, those with metabolic syndrome, or South Asian/African-Caribbean descent 4

4. Abrupt discontinuation of clonidine: Always taper centrally acting agents to avoid severe withdrawal syndrome 10

5. Ignoring edema with amlodipine: This is the primary driver of discontinuation (24% incidence) and significantly impacts quality of life 1, 2